News
NEW YORK, NY, USA I August 15, 2025 I Pfizer Inc. (NYSE: PFE) today announced results from the Phase 3 THRIVE-131 study evaluating inclacumab, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback